Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including multiple sclerosis, Parkinson’s disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
02/12/16 SC 13G/A Amended Statement of Ownership
02/11/16 8-K Current report filing
02/10/16 SC 13G/A Amended Statement of Ownership
02/05/16 4 Statement of Changes in Beneficial Ownership

Stock Quote

ACOR (Common Stock) $ 33.63 +0.15 (+0.45%) Volume: 924,499 MORE February 12, 2016

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *